A Computational Study of Some Benzenesulfonamide Derivatives as HIV- 1 Protease Enzyme Inhibitors: Three-Dimensional Quantitative Structure-Activity Relationship and Molecular Docking

References

• 1.
  Weber IT, Wang YF, Harrison RW. HIV Protease: Historical Perspective and Current Research. Viruses. 2021;13(5). [PubMed ID:34066370]. [PubMed Central ID:PMC8148205]. https://doi.org/10.3390/v13050839.
• 2.
  Sankaran SV, Krishnan SR, Sayed Y, Gromiha MM. Mechanism of drug resistance in HIV-1 protease subtype C in the presence of Atazanavir. Curr Res Struct Biol. 2024;7:100132. [PubMed ID:38435053]. [PubMed Central ID:PMC10907180]. https://doi.org/10.1016/j.crstbi.2024.100132.
• 3.
  Zulfiqar HF, Javed A, Sumbal, Afroze B, Ali Q, Akbar K, et al. HIV Diagnosis and Treatment through Advanced Technologies. Front Public Health. 2017;5:32. [PubMed ID:28326304]. [PubMed Central ID:PMC5339269]. https://doi.org/10.3389/fpubh.2017.00032.
• 4.
  Chuntakaruk H, Hengphasatporn K, Shigeta Y, Aonbangkhen C, Lee VS, Khotavivattana T, et al. FMO-guided design of darunavir analogs as HIV-1 protease inhibitors. Sci Rep. 2024;14(1):3639. [PubMed ID:38351065]. [PubMed Central ID:PMC10864397]. https://doi.org/10.1038/s41598-024-53940-1.
• 5.
  Dakshinamoorthy A, Asmita A, Senapati S. Comprehending the Structure, Dynamics, and Mechanism of Action of Drug-Resistant HIV Protease. ACS Omega. 2023;8(11):9748-63. [PubMed ID:36969469]. [PubMed Central ID:PMC10034783]. https://doi.org/10.1021/acsomega.2c08279.
• 6.
  Tozser J. Stages of HIV replication and targets for therapeutic intervention. Curr Top Med Chem. 2003;3(13):1447-57. [PubMed ID:14529520]. https://doi.org/10.2174/1568026033451781.
• 7.
  Mahanti M, Bhakat S, Nilsson UJ, Soderhjelm P. Flap Dynamics in Aspartic Proteases: A Computational Perspective. Chem Biol Drug Des. 2016;88(2):159-77. [PubMed ID:26872937]. https://doi.org/10.1111/cbdd.12745.
• 8.
  Meng S, Gao Y, Qiang G, Hu Z, Shan Q, Wang J, et al. Rational design, synthesis and biological evaluation of novel HIV-1 protease inhibitors containing 2-phenylacetamide derivatives as P2 ligands with potent activity against DRV-Resistant HIV-1 variants. Bioorg Med Chem Lett. 2024;101:129651. [PubMed ID:38342391]. https://doi.org/10.1016/j.bmcl.2024.129651.
• 9.
  Nascimento A, Fernandes RP, Quijia C, Araujo VHS, Pereira J, Garcia JS, et al. Pharmacokinetic Parameters of HIV-1 Protease Inhibitors. Chem Med Chem. 2020;15(12):1018-29. [PubMed ID:32390304]. https://doi.org/10.1002/cmdc.202000101.
• 10.
  Zephyr J, Kurt Yilmaz N, Schiffer CA. Viral proteases: Structure, mechanism and inhibition. Enzymes. 2021;50:301-33. [PubMed ID:34861941]. [PubMed Central ID:PMC8595904]. https://doi.org/10.1016/bs.enz.2021.09.004.
• 11.
  Voshavar C. Protease Inhibitors for the Treatment of HIV/AIDS: Recent Advances and Future Challenges. Curr Top Med Chem. 2019;19(18):1571-98. [PubMed ID:31237209]. https://doi.org/10.2174/1568026619666190619115243.
• 12.
  Aruksakunwong O, Promsri S, Wittayanarakul K, Nimmanpipug P, Lee V, Wijitkosoom A, et al. Current Development on HIV-1 Protease Inhibitors. Current Computer Aided-Drug Design. 2007;3(3):201-13. https://doi.org/10.2174/157340907781695431.
• 13.
  Nastri BM, Pagliano P, Zannella C, Folliero V, Masullo A, Rinaldi L, et al. HIV and Drug-Resistant Subtypes. Microorganisms. 2023;11(1). [PubMed ID:36677513]. [PubMed Central ID:PMC9861097]. https://doi.org/10.3390/microorganisms11010221.
• 14.
  Rajendran M, Ferran MC, Mouli L, Babbitt GA, Lynch ML. Evolution of drug resistance drives destabilization of flap region dynamics in HIV-1 protease. Biophys Rep (N Y). 2023;3(3):100121. [PubMed ID:37662576]. [PubMed Central ID:PMC10469570]. https://doi.org/10.1016/j.bpr.2023.100121.
• 15.
  Shaker B, Ahmad S, Lee J, Jung C, Na D. In silico methods and tools for drug discovery. Comput Biol Med. 2021;137:104851. [PubMed ID:34520990]. https://doi.org/10.1016/j.compbiomed.2021.104851.
• 16.
  Verma J, Khedkar VM, Coutinho EC. 3D-QSAR in drug design--a review. Curr Top Med Chem. 2010;10(1):95-115. [PubMed ID:19929826]. https://doi.org/10.2174/156802610790232260.
• 17.
  Kubinyi H. QSAR and 3D QSAR in drug design Part 1: methodology. Drug Discovery Today. 1997;2(11):457-67. https://doi.org/10.1016/s1359-6446(97)01079-9.
• 18.
  Kubinyi H. QSAR and 3D QSAR in drug design Part 2: applications and problems. Drug Discovery Today. 1997;2(12):538-46. https://doi.org/10.1016/s1359-6446(97)01084-2.
• 19.
  Akamatsu M. Current state and perspectives of 3D-QSAR. Curr Top Med Chem. 2002;2(12):1381-94. [PubMed ID:12470286]. https://doi.org/10.2174/1568026023392887.
• 20.
  Cramer RD, Patterson DE, Bunce JD. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc. 1988;110(18):5959-67. [PubMed ID:22148765]. https://doi.org/10.1021/ja00226a005.
• 21.
  Klebe G, Abraham U, Mietzner T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem. 1994;37(24):4130-46. [PubMed ID:7990113]. https://doi.org/10.1021/jm00050a010.
• 22.
  Ali A, Reddy GS, Nalam MN, Anjum SG, Cao H, Schiffer CA, et al. Structure-based design, synthesis, and structure-activity relationship studies of HIV-1 protease inhibitors incorporating phenyloxazolidinones. J Med Chem. 2010;53(21):7699-708. [PubMed ID:20958050]. [PubMed Central ID:PMC2996262]. https://doi.org/10.1021/jm1008743.
• 23.
  Clark M, Cramer RD, Van Opdenbosch N. Validation of the general purpose tripos 5.2 force field. J Comput Chem. 2004;10(8):982-1012. https://doi.org/10.1002/jcc.540100804.
• 24.
  Kearsley SK, Smith GM. An alternative method for the alignment of molecular structures: Maximizing electrostatic and steric overlap. Tetrahedron Comput Methodol. 1990;3(6):615-33. https://doi.org/10.1016/0898-5529(90)90162-2.
• 25.
  Cramer RD, Bunce JD, Patterson DE, Frank IE. Crossvalidation, Bootstrapping, and Partial Least Squares Compared with Multiple Regression in Conventional QSAR Studies. Quantitative Structure-Activity Relationships. 2006;7(1):18-25. https://doi.org/10.1002/qsar.19880070105.
• 26.
  Kellogg GE, Semus SF, Abraham DJ. HINT: a new method of empirical hydrophobic field calculation for CoMFA. J Comput Aided Mol Des. 1991;5(6):545-52. [PubMed ID:1818090]. https://doi.org/10.1007/BF00135313.
• 27.
  Waller CL. A comparative QSAR study using CoMFA, HQSAR, and FRED/SKEYS paradigms for estrogen receptor binding affinities of structurally diverse compounds. J Chem Inf Comput Sci. 2004;44(2):758-65. [PubMed ID:15032558]. https://doi.org/10.1021/ci0342526.
• 28.
  Golbraikh A, Tropsha A. Beware of q2! J Mol Graph Model. 2002;20(4):269-76. [PubMed ID:11858635]. https://doi.org/10.1016/s1093-3263(01)00123-1.
• 29.
  Bungard CJ, Williams PD, Schulz J, Wiscount CM, Holloway MK, Loughran HM, et al. Design and Synthesis of Piperazine Sulfonamide Cores Leading to Highly Potent HIV-1 Protease Inhibitors. ACS Med Chem Lett. 2017;8(12):1292-7. [PubMed ID:29259750]. [PubMed Central ID:PMC5733263]. https://doi.org/10.1021/acsmedchemlett.7b00386.
• 30.
  Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605-12. [PubMed ID:15264254]. https://doi.org/10.1002/jcc.20084.
• 31.
  Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. Methods Mol Biol. 2015;1263:243-50. [PubMed ID:25618350]. https://doi.org/10.1007/978-1-4939-2269-7_19.
• 32.
  Pires DE, Blundell TL, Ascher DB. pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. J Med Chem. 2015;58(9):4066-72. [PubMed ID:25860834]. [PubMed Central ID:PMC4434528]. https://doi.org/10.1021/acs.jmedchem.5b00104.
• 33.
  Sander T, Freyss J, von Korff M, Reich JR, Rufener C. OSIRIS, an entirely in-house developed drug discovery informatics system. J Chem Inf Model. 2009;49(2):232-46. [PubMed ID:19434825]. https://doi.org/10.1021/ci800305f.
• 34.
  Khedkar VM, Ambre PK, Verma J, Shaikh MS, Pissurlenkar RR, Coutinho EC. Molecular docking and 3D-QSAR studies of HIV-1 protease inhibitors. J Mol Model. 2010;16(7):1251-68. [PubMed ID:20069323]. https://doi.org/10.1007/s00894-009-0636-5.
• 35.
  Tong J, Wu Y, Bai M, Zhan P. 3D-QSAR and molecular docking studies on HIV protease inhibitors. J Mol Structure. 2017;1129:17-22. https://doi.org/10.1016/j.molstruc.2016.09.052.
• 36.
  Halder AK. Finding the structural requirements of diverse HIV-1 protease inhibitors using multiple QSAR modelling for lead identification. SAR QSAR Environ Res. 2018;29(11):911-33. [PubMed ID:30332922]. https://doi.org/10.1080/1062936X.2018.1529702.
• 37.
  Tong J-B, Bai M, Zhao X. 3D-QSAR and docking studies of HIV-1 protease inhibitors using R-group search and Surflex-dock. Med Chem Res. 2016;25(11):2619-30. https://doi.org/10.1007/s00044-016-1701-0.
• 38.
  Fang R-J, Zhang Y-J, Wang W-X, Wu T-L, Zhang S-J, He Y-Y, et al. The 3D-QSAR Study, Molecular Docking, and ADMET Analysis of Darunavir Derivatives of HIV-1 Protease Inhibitors. Letters Drug Design Discovery. 2024;21(13):2590-603. https://doi.org/10.2174/1570180820666230818100059.
• 39.
  Hamdache B, Tabti K, Er-rajy M, Dib M, ElFarouki K, Ouchetto K, et al. QSAR Modeling and Molecular Docking Studies of New Substituted Pyrazolyl-Pyrimidinones as Potent HIV-1 Inhibitors. Curr Chem Biol. 2024;18(3):157-75. https://doi.org/10.2174/0122127968317638241014090751.